Last reviewed · How we verify
NCT05177120: FMF
Central Sensitization in Familial Mediterranean Fever (FMF)
trial testing Central Sensitization Inventory in Familial Mediterranean Fever in 100 participants. Completed in 3 August 2022.
10 April 2022
Quick facts
| Lead sponsor | Marmara University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 June 2021 |
| Primary completion | 10 April 2022 |
| Estimated completion | 3 August 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Central Sensitization Inventory
- Short form-36
- Pittsburgh Sleep Quality Index
- Health assessment questionnaire
- Hospital anxiety and depression scale
- Fibromyalgia rapid screening tool
- Familial Mediterranean Fever Quality of life scale
Conditions studied
- Familial Mediterranean Fever — all drugs for Familial Mediterranean Fever →
- Central Sensitisation — all drugs for Central Sensitisation →
Sponsor
Marmara University
Who can join
Adults 18 to 75, any sex, with Familial Mediterranean Fever or Central Sensitisation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Familial Mediterranean Fever (FMF) is an autosomal recessive inherited disease with a course of autoinflammation, which is characterized by the episodes of fever and serositis. Central sensitization (CS) is defined as increased response to normal or sub-threshold stimuli of central nervous system and its close relationship with many rheumatological diseases has been demonstrated in several studies. However, there are no data on the frequency of CS in FMF patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05177120
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Central Sensitization Inventory
Trials testing the same drug.
- NCT06770634 — Investigation of Central Sensitization and Associated Factors in Patients With Lipedema · recruiting
- NCT06948903 — Relationship Between Central Sensitization Symptoms and Cognitive Dysfunction in Fibromyalgia · recruiting
- NCT05021783 — The Relationship Between Magnetic Resonance Imaging (MRI) Scores and Sensory Testing in Axial Spondyloarthritis · completed
- NCT04485078 — Investigation of Central Sensitization Frequency and Related Factors in Axial Spondyloarthritis Patients · completed
Other recruiting trials for Familial Mediterranean Fever
Currently open trials in the same condition.
- NCT07129538 — Outcomes of Inspiratory Muscle Training in FMF Adolescents · NA · recruiting
- NCT07130305 — is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever · NA · recruiting
- NCT07130318 — Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise · NA · recruiting
- NCT07128225 — Health-related Quality of Life, Electrocardiographic and Holter Findings in Children With Familial Mediterranean Fever · active not recruiting
- NCT06338891 — Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks · recruiting
Other Marmara University trials
Trials by the same sponsor.
- NCT07533734 — The Effects of an Augmented Reality-Based Mirror Therapy System in Patients With Stroke · NA · not yet recruiting
- NCT07474181 — Simulation-Based Training for Urinary Catheterization Skills in Nursing Students · NA · not yet recruiting
- NCT07486349 — Shoulder Pericapsular Block Versus Interscalene Block in Arthroscopic Shoulder Surgery · NA · not yet recruiting
- NCT07468110 — Evaluation Of The Relationship Between The Conut Score And Balance And Functional Status In Patients With Chronic Stroke · recruiting
- NCT07468097 — The Impact of Metabolic Status on Pain and Central Sensitization in Women With Lipedema: A Cross-Sectional Observational · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05177120 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Marmara University
- Last refreshed: 10 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05177120.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing